OPPM
Opus Point Partners Management Portfolio holdings
AUM
$46.9M
This Quarter Return
-15.81%
1 Year Return
-4.17%
3 Year Return
+83.22%
5 Year Return
+175.29%
10 Year Return
–
AUM
$107M
AUM Growth
-$42.4M
(-28%)
Cap. Flow
-$11.9M
Cap. Flow
% of AUM
-11.13%
Top 10 Holdings %
Top 10 Hldgs %
40.3%
Holding
64
New
7
Increased
16
Reduced
26
Closed
10
Top Buys
| 1 |
Pfizer
PFE
|
$3.26M |
| 2 |
ProShares Ultra NASDAQ Biotechnology
BIB
|
$2.03M |
| 3 |
Alnylam Pharmaceuticals
ALNY
|
$1.72M |
| 4 |
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
|
$930K |
| 5 |
SNR
NEW SENIOR INVESTMENT GROUP INC.
SNR
|
$927K |
Top Sells
| 1 |
iShares Biotechnology ETF
IBB
|
$10.7M |
| 2 |
Gilead Sciences
GILD
|
$2.79M |
| 3 |
NSTG
NanoString Technologies, Inc.
NSTG
|
$1.5M |
| 4 |
Xencor
XNCR
|
$1.32M |
| 5 |
Amgen
AMGN
|
$1.29M |
Sector Composition
| 1 | Healthcare | 84.87% |
| 2 | Real Estate | 0.86% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
51
Gilead Sciences
GILD
$141B
| $301K | 0.23% |
3,282
-30,418
| -90% | -$2.79M |
|
52
BioCryst Pharmaceuticals
BCRX
$1.74B
| – | – |
-100,000
| Closed | -$1.03M |
|
53
Eledon Pharmaceuticals
ELDN
$154M
| – | – |
-383
| Closed | -$541K |
|
|
54
iShares Biotechnology ETF
IBB
$5.69B
| – | – |
-94,800
| Closed | -$10.7M |
|
55
iShares Russell 2000 ETF
IWM
$66.8B
| – | – |
0
| – | – |
|
56
KalVista Pharmaceuticals
KALV
$712M
| – | – |
-1,250
| Closed | -$63K |
|
57
MacroGenics
MGNX
$121M
| – | – |
-30,000
| Closed | -$929K |
|
58
Novavax
NVAX
$1.18B
| – | – |
0
| – | – |
|
|
59
Xencor
XNCR
$586M
| – | – |
-90,000
| Closed | -$1.32M |
|
|
NSTG
60
DELISTED
NanoString Technologies, Inc.
NSTG
| – | – |
-102,200
| Closed | -$1.5M |
|
|
INFI
61
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
| – | – |
-30,000
| Closed | -$236K |
|
|
PLXP
62
DELISTED
PLx Pharma Inc. Common Stock
PLXP
| – | – |
-3,125
| Closed | -$280K |
|
|
SRRA
63
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| – | – |
-750
| Closed | -$451K |
|